NCT05984199
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05984199
Title Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vor Biopharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego Moores Cancer Center La Jolla California 92093 United States Details
Stanford Cancer Institute Stanford California 94305 United States Details
Miami Cancer Institute Miami Florida 33176 United States Details
Winship Cancer Institute Emory University Atlanta Georgia 30322 United States Details
The University of Kansas Cancer Center Fairway Kansas 66205 United States Details
National Institutes of Health, Clinical Center Bethesda Maryland 20892 United States Details
University of Michigan Health Ann Arbor Michigan 48109 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Masonic Cancer Center, University of Minnesota Minneapolis Minnesota 55455 United States Details
Washington University School of Medicine Siteman Cancer Center St Louis Missouri 63110 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Icahn School of Medicine at Mount Sinai New York New York 10029 United States Details
University Hospitals Seidman Cancer Center Cleveland Ohio 44106 United States Details
University of Utah Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field